Dade Behring to distribute ZymeTx influenza diagnostic:
This article was originally published in Clinica
Dade Behring is to handle distribution for ZymeTx' ZstatFlu influenza diagnostic to 25,000 US hospital and reference laboratories. ZymeTx claimed a 50% share of the 230,000 point-of-care tests administered in physicians' offices last year, but said the reference labs conducted more than twice as many tests. With the advent of effective anti-flu therapeutics, that market is predicted to grow to 20 million prescriptions by 2004/2005, with a potential one-to-one ratio between diagnostics and therapeutics, according to ZymeTx.